EP3662937A1 - Hämostatisches material und wundverbandmaterial damit - Google Patents

Hämostatisches material und wundverbandmaterial damit Download PDF

Info

Publication number
EP3662937A1
EP3662937A1 EP17920080.3A EP17920080A EP3662937A1 EP 3662937 A1 EP3662937 A1 EP 3662937A1 EP 17920080 A EP17920080 A EP 17920080A EP 3662937 A1 EP3662937 A1 EP 3662937A1
Authority
EP
European Patent Office
Prior art keywords
wound
hemostatic
cationized cellulose
wound dressing
cellulose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP17920080.3A
Other languages
English (en)
French (fr)
Other versions
EP3662937A4 (de
Inventor
Kazuhiko Shibata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Artisan Lab Co Ltd
Nipro Corp
Original Assignee
Artisan Lab Co Ltd
Nipro Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Artisan Lab Co Ltd, Nipro Corp filed Critical Artisan Lab Co Ltd
Publication of EP3662937A1 publication Critical patent/EP3662937A1/de
Publication of EP3662937A4 publication Critical patent/EP3662937A4/de
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/08—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/28—Polysaccharides or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001—Use of materials characterised by their function or physical properties
    • A61L24/0015—Medicaments; Biocides
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B15/00—Preparation of other cellulose derivatives or modified cellulose, e.g. complexes
    • C08B15/05—Derivatives containing elements other than carbon, hydrogen, oxygen, halogens or sulfur
    • C08B15/06—Derivatives containing elements other than carbon, hydrogen, oxygen, halogens or sulfur containing nitrogen, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/23—Carbohydrates
    • A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/04—Materials for stopping bleeding

Definitions

  • the present invention relates to a hemostatic material, and a wound dressing containing the hemostatic material.
  • Known skin wound healing mechanisms are such that (1) when the skin is damaged, platelets gather around and in the wound and coagulate the blood to stop bleeding, (2) neutrophils and macrophages gather around the wound to phagocytose and remove necrotic tissue and bacteria, (3) fibroblasts gather to shrink the wound, and (4) epidermal cells migrate and gather to epithelialize the wound.
  • cytokines For wound healing, various living cells are required to gather and function around and in the wound as described above. Many cytokines including growth factors summon cells required for wound healing to the wound. It is important for quick wound healing to maintain an environment where cells gathered around and in the wound by cytokines can actively function.
  • a wound dressing is a member that provides a moist environment by covering a wounded site and promotes wound healing.
  • Hydrogels which are widely used as components of wound dressings, have no effect in regard to as antibacterial and hemostatic properties and, it is not easy to degrade some kinds of hydrogels by microorganisms when buried in the soil. For this reason, some kinds of hydrogels are disposed by incineration or burying, and may generate dioxin if the temperature of a combustion furnace falls upon incineration. In the case of disposal by burying, securing of a burial place is becoming difficult, and thus a product causing no dioxin generation by incineration and having a small environmental burden is required.
  • chitosan could be an allergen leading to shellfish allergy, and the use of a hemostatic material or a wound dressing made of chitosan as a raw material may cause a severe allergic reaction in a person who is allergic to shellfish.
  • a formulation produced with chitosan as a raw material is used for wounds, and specifically, when such a formulation is prescribed for a person with a shellfish allergy, care should be taken and another formulation should be used if possible.
  • there is a potential risk of developing allergy since a person being prescribed may not be previously noticed that he/she has a shellfish allergy.
  • crab or shrimp crusts which are not originally sterile, are used as a raw material for mass production of chitosan.
  • endotoxins which are secreted by bacteria and harmful to human bodies, when chitosan is isolated.
  • pathological conditions induced by endotoxins include lethal shock, fever, activation of complements, activation of leukocytes, and damage to vascular endothelial cells, etc.
  • the present invention has been achieved in view of such circumstances, and an object of the present invention is to provide a hemostatic material and a wound dressing containing the hemostatic material, which can be used safely for more people, and also suppresses bleeding and infection which hinder wound healing, and hardly causes complication.
  • a first aspect of the present invention provides a hemostatic material comprising cationized cellulose.
  • Another aspect of the present invention provides a wound dressing comprising a hemostatic material containing cationized cellulose as a component.
  • Yet another aspect of the present invention provides a wound dressing comprising cationized cellulose.
  • Cellulose is a natural compound produced by plants in their bodies through photosynthesis.
  • wound dressings mainly made of cellulose such as Dermafill and XCell Cellulose Wound Dressings
  • wound dressings containing carboxymethyl cellulose which is a cellulose derivative
  • carboxymethyl cellulose which is a cellulose derivative
  • these products have water-holding capacity, but lack antibacterial and hemostatic properties. Therefore, wound dressings containing cellulose or carboxymethyl cellulose as a main component cannot suppress internal bacterial growth and bleeding complications when wounds are covered.
  • cationized cellulose has a positively charged functional group and thus has both hemostatic and antibacterial properties.
  • the hemostatic property was examined and confirmed using activated clotting time.
  • antibacterial property it was confirmed that cationized cellulose has an antibacterial property through culturing of skin indigenous bacteria of medical practitioners in an agar medium, followed by formation of a blocking circle around the filter paper impregnated with the gelled cationized cellulose during bacterial culture.
  • cationized cellulose is contained in a hemostatic material or a wound dressing that directly contacts a wound.
  • the hemostatic material or the wound dressing directly contacts bacteria at the wound site, whereby the cationized cellulose can exhibit antibacterial activity due to the positive charge of the cationized cellulose.
  • the above cationized cellulose may be of formula (1): wherein
  • the at least one R 1 represents -CH 2 CH 2 O-CH 2 CH(OH)CH 2 -N + (R 3 )(R 4 )(R 5 ) ⁇ X - , and R 3 , R 4 and R 5 may represent a methyl or an ethyl group.
  • the at least one R 1 may represent - CH 2 CH(OH)CH 2 N + (R 3 )(R 4 )(R 5 ) ⁇ X - , and R 3 , R 4 and R 5 may each represent a methyl or an ethyl group.
  • the anionic group may be a halide ion, a phosphoric acid ester group, a carboxyl group, a sulfonic acid group, a sulfuric acid ester group or the like.
  • the halide ion may be a fluoride ion, a chloride ion, a bromide ion, or an iodide ion.
  • At least one of the other R 1 may also represent -(CH 2 CH 2 O) m H.
  • the water-holding capacity of cationized cellulose can be increased. This broadens the range of applicable conditions and makes it possible to produce a wound dressing more suitable for moist treatment.
  • the hemostatic material and the wound dressing according to the present invention can be used safely for more people, and, can promote wound healing. Further, compared to commonly used hydrogels, the hemostatic material and the wound dressing function to suppress bleeding, infection and the like, and thus have high safety and can lower risks such as cellulitis and septicemia. Furthermore, unlike chitosan, a hemostatic and a wound dressing, which are free of shellfish allergy concerns, can be provided.
  • hemostatic material and the wound dressing according to the present invention will be described.
  • the general formula representing cationized cellulose contained in the hemostatic material and the wound dressing according to the present embodiment is shown below. Any of the 2-, 4- and 6-position hydroxyl groups of glucose that forms cellulose is modified with a cationized functional group.
  • the cationized cellulose used in the present embodiment can be purchased as a commercial product, and can be synthesized by applying a general synthesis method employed for chemical modification of glucan.
  • 3-chloro-2-hydroxypropyltrimethylammonium chloride (2.3 g) as a cationizing agent is added to a solution prepared by dissolving 1.0 g of cellulose in 20 mL of a 1N sodium hydroxide aqueous solution, and then the solution is stirred at 30°C to 50°C.
  • the resulting solution is neutralized with 4N acetic acid and then separated by dialysis membrane using distilled water.
  • the obtained solution is lyophilized, so that a desired product can be obtained.
  • Cellulose (2.0 g) is reacted with ethylene oxide under known conditions to synthesize hydroxyethyl cellulose.
  • Glycidyl trimethyl ammonium chloride (4.5 g) as a cationizing agent is added to a solution prepared by dissolving the obtained hydroxyethyl cellulose in 20 mL of a 1N sodium hydroxide aqueous solution, and then the solution is stirred at 30°C to 50°C.
  • the resulting solution is neutralized with 4N acetic acid and then separated by dialysis membrane using distilled water.
  • the obtained solution is lyophilized, so that a desired product can be obtained.
  • a cationized cellulose having different types of substituents can be synthesized in the same manner as the above synthesis example.
  • a solvent to be used herein an alcohol such as methanol or ethanol, acetonitrile or the like may be added depending on the solubility of the substrate.
  • the equivalent of the cationizing agent to be reacted can be appropriately adjusted according to the degree of cationization of target cationized cellulose.
  • the degree of bacterial sensitivity to the cationized cellulose according to the present invention was confirmed by a disc method.
  • ASONE SANYFOODS Petan Check 25 PT4025 standard agar medium was used to culture bacteria attached to the bare hands of 3 medical personnels. Bacteria actively forming colonies of these bacteria were collected with sterile cotton swabs and applied in equal amounts to three media (Medium 1, Medium 2, Medium 3).
  • As cationized cellulose 1 g of hydroxyethyl cellulose hydroxypropyl trimethyl ammonium chloride ether (Kao POIZ C-60H, C-150 L) was used, and 4 mL of water for injection was added thereto and then the mixture was stirred for 3 minutes. Filter paper was impregnated with the resulting gelled sample and then placed on the above media. After culturing at 37°C for 48 hours, the formation of inhibition circles was confirmed.
  • the bacteria grew in the media were, as a result of identification, a mixture of staphylococci and bacteria of the genus Bacillus in Medium 1, bacteria of the genus Bacillus in Medium 2, and staphylococci in Medium 3. This successfully confirmed that the cationized cellulose has antibacterial activity.
  • the hemostatic property of the cationized cellulose according to the present invention was confirmed by comparing the clotting time with that of a control substance using a dedicated cartridge for blood coagulation measurement device (JMS Co., Ltd.).
  • the average weight was determined by measuring 10 pieces of diatomaceous earth originally enclosed in dedicated cartridges for a blood coagulation measurement device specialized for an elapsed-time timer, "ACTester” (QUEST Medical, Inc.) for measuring clotting time.
  • the average weight of the diatomaceous earth pieces in the lot used herein was 0.015 g, and thus cartridges were each prepared by replacement with cationized cellulose (Kao POIZ C-60H, C-150 L) having the same weight as that of the diatomaceous earth piece.
  • Whole blood (0.7 mL) was collected from a subject (the inventor in this case) using a needle for injection with the outer diameter of 0.7 to 1.2 mm (22 to 18 G) of a needle tube and a 1 cc syringe.
  • a needle for injection with the outer diameter of 0.7 to 1.2 mm (22 to 18 G) of a needle tube and a 1 cc syringe.
  • 0.7 mL or less of blood was injected into a dedicated cartridge for blood coagulation measurement device.
  • 0.7 mL of air in the cartridge was withdrawn.
  • the cartridge was set in the ACTest tube holder of the device body to measure the activated clotting time.
  • results could confirm that the cationized cellulose has effects of promoting coagulation and stopping bleeding. Further, the results could also confirm that the cationized cellulose has hemostatic property higher than that of chitosan which is generally used for wound dressings.
  • the inventors of the present invention have discovered that through chemical modification of cellulose with a cationized functional group, a hemostatic material and a new wound dressing having an antibacterial function and a hemostatic function can be provided. Advantages brought by such hemostatic and antibacterial functions to wound healing are discussed below.
  • KALTOSTAT registered trademark
  • alginic acid has a weak hemostatic function compared to chitosan ( Syota Suzuki, Kazuhiko Shibata, Randomized Trial comparing New Chitosan-Based Bandage with Kaltostat Hemostatic Dressing to Control Bleeding from Hemodialysis Puncture Site, Nephrol. Dial.
  • chitosan has low water-holding ability, so neither is sufficient as bases for moist treatment.
  • a dressing having a hemostatic function higher than that of chitosan can be provided.
  • a method that has been widely spread involves frequently replacing dressings attached to a wound site and cleaning the wound site every replacement. This is because a problem is becoming clear such that sealing the wound site by leaving a dressing applied to the wound site results in the formation of an environment suitable for the growth of bacteria present at the wound site, which in turn delays the healing of the wound site.
  • the hemostatic material and the wound dressing according to the present invention can solve the problems as described above by containing positively charged cationized cellulose.
  • the bacterial cell surface at around neutrality is negatively charged by dissociation of phosphate and carboxyl groups.
  • Positively charged cationized cellulose which is present in the vicinity of the surface where a hemostatic contacts the wound, or the surface of the wound dressing, electrostatically adsorbs to the bacterial cell surface, so that bacteria can be efficiently captured.
  • bacteria captured in the vicinity of the surface where a hemostatic comes into contact with the wound and the surface of the wound dressing are incorporated into the hemostatic material and the wound dressing, so that the bacteria can be removed from the wound site and wound healing can be accelerated.
  • the hemostatic material and the wound dressing can be used to stop bleeding.
  • the use of the wound dressing containing cationized cellulose having an antibacterial effect according to the present embodiment can reduce the adverse effects of bacteria more effectively than the conventional method that involves continuously applying a wound healing drug lacking such antibacterial effect.
  • the use of a chitosan preparation requires a caution when it is applied to a person with a shellfish allergy.
  • the cationized cellulose is less likely to be of concern and can be safely used by more people.
  • cationized cellulose has a high water-holding capacity, and thus is gelled by incorporating excess water at the wound site. This makes it possible to maintain an ideal environment for leaving the exudate containing various substances important for wound healing on the surface of the wound for a long time while suppressing bacterial growth at the wound site.
  • cationized cellulose can be gelled. Accordingly, a hemostatic material containing cationized cellulose can be applied directly to the wound site. Even if the wound is irregular in shape, the hemostatic is applied in this manner, so as to be able to ensure its contact with the wound surface. Moreover, the applied gel is covered and pressed with a gauze, a film or the like, so that hemostasis can be achieved. After confirmation of hemostasis, it is also possible to release the pressure and use continuously the gel as a wound dressing.
  • cationized cellulose can be made into a sheet-like film. Specifically, once cationized cellulose is dissolved in a solvent such as water or alcohol to be gelled, the solvent can be forcibly discharged from the gel to form a film.
  • the film can be adjusted in thickness, density and the like according to the purpose of use.
  • cationized cellulose as a simple substance or a mixture of cationized cellulose and a base may be formed into a film. If a water-soluble adhesive is used for adhering the wound dressing to the skin, the cationized cellulose in the film does not contact dry skin, while on the wound surface the water-soluble adhesive is dissolved because of an exudate from the wound. Hence, the cationized cellulose can be caused to contact only the wound surface.
  • the opposite side of the contact surface can be reinforced or provided with additional performance through the use of a film that impedes the transpiration of water, or a cloth, non-woven fabric or the like that causes the water to transpirate appropriately when there is a large amount of an exudate.
  • preparations are used properly such that a preparation with a waterproof film is used in a dry state and a preparation with a water-permeable sheet is used when exfoliation likely takes place due to a large amount of an exudate and waterproofing.
  • coatings suitable for various wounds can be prepared.
  • the obtained cationized cellulose can be gelled and contained in the wound dressing.
  • Cationized cellulose has a water-holding capacity higher than that of chitosan. Therefore, the cationized cellulose is formed into a sheet or gel, the sheet or gel is applied to the wound site, and then a pad having water absorbability is applied thereon, so that even when a large amount of an exudate is generated from the wound site, the pad absorbs excess water and thus the moist environment at the wound site can be properly maintained as an environment required for healing.
  • cationized cellulose has an antibacterial property. Therefore, even in a situation where cationized cellulose in the form of film or gel contacts directly the wound site, an antibacterial environment more suitable for healing can be maintained until wound healing.
  • a waterproof film may be replaced by a breathable film in case the amount of an exudate is further increased.
  • the wound dressing according to the present embodiment is made into forms as described above, so that a user can conveniently apply the wound dressing to a wound site.
  • cationized cellulose can also be used as a hemostatic gauze by mixing cationized cellulose with or adsorbing cationized cellulose to cloth or non-woven fabric.
  • the wound dressing in the present embodiment may be a wound dressing such that after cationized cellulose is gelled and then the gel is applied to a wound site, the portion coated therewith can be covered with a water-permeable or waterproof sheet as necessary.
  • the wound dressing can be easily applied to the wound site even if the wound site has a complicated shape such as a cut and a deep crease.
  • the wound dressing in the present embodiment can be made into powder by adding a suitable base to cationized cellulose, or by performing processing such as spray drying or lyophilization. If there is a large amount of bleeding or an exudate from the wound site, the powder is sprinkled over the wound site to cover the site, and then the site is covered with gauze, a waterproof film, a water-absorbable sheet or the like. With such a form, the wound dressing can be easily used as a hemostatic at an early stage of injury, and the wound dressing according to the present embodiment can be applied with high freedom to cover wound sites in various shapes.
  • cellulose is chemically modified with a cationized functional group to positively charge the cellulose, thereby suppressing bacterial growth that hinders wound healing. Therefore, a hemostatic material and a wound dressing having antibacterial property better than that of conventionally used materials can be provided.
  • positively charged cationized cellulose is used, so that a wound dressing having a higher hemostatic effect can be provided.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Materials Engineering (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Surgery (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Materials For Medical Uses (AREA)
EP17920080.3A 2017-08-01 2017-08-01 Hämostatisches material und wundverbandmaterial damit Pending EP3662937A4 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2017/027890 WO2019026177A1 (ja) 2017-08-01 2017-08-01 止血材およびそれを含有する創傷被覆材

Publications (2)

Publication Number Publication Date
EP3662937A1 true EP3662937A1 (de) 2020-06-10
EP3662937A4 EP3662937A4 (de) 2021-03-10

Family

ID=65233167

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17920080.3A Pending EP3662937A4 (de) 2017-08-01 2017-08-01 Hämostatisches material und wundverbandmaterial damit

Country Status (4)

Country Link
US (2) US20210085820A1 (de)
EP (1) EP3662937A4 (de)
CN (2) CN115475276A (de)
WO (1) WO2019026177A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852630B2 (en) * 2008-05-13 2014-10-07 Yale University Chimeric small molecules for the recruitment of antibodies to cancer cells
AU201716716S (en) * 2017-05-11 2017-11-21 MAƒA¶LNLYCKE HEALTH CARE AB Wound dressings
EP4082586A4 (de) * 2019-12-26 2023-12-27 Artisan Lab Co., Ltd. Verfahren zur herstellung von material zur lokalen hämostase und material zur lokalen hämostase

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50150296A (de) 1974-05-25 1975-12-02
US4921691A (en) * 1985-08-22 1990-05-01 Stockel Richard F Spray on wound dressing compositions
JPS62183768A (ja) * 1986-02-10 1987-08-12 テルモ株式会社 生体適合性材料およびその製造方法
EP0243151B1 (de) * 1986-04-22 1992-12-16 Ajinomoto Co., Inc. Modifiziertes, durch Mikroorganismen hergestelltes Zellulose-Gel und sein Komplex mit tierischen Zellen
JP2606213B2 (ja) * 1986-04-22 1997-04-30 味の素株式会社 修飾された微生物産生セルロースのゲルおよび動物細胞膜との複合体
GB9808461D0 (en) 1998-04-22 1998-06-17 Innovative Tech Ltd Solid borate-diol interaction products
CN1185263C (zh) * 2001-10-08 2005-01-19 东华大学 医用可吸收氧化再生纤维素止血材料的制备方法
US20030118651A1 (en) * 2001-12-21 2003-06-26 Jampani Hanuman B. Bio-compatible means for controlled drug delivery to tissue and method of use
JP2011507860A (ja) * 2007-12-21 2011-03-10 コーダ セラピューティクス， インコーポレイテッド 異常瘢痕または過剰瘢痕の治療のための抗コネキシンポリヌクレオチドおよび抗コネキシンペプチドの使用
GB2461019B (en) 2008-04-25 2013-06-05 Medtrade Products Ltd Haemostatic material
JP5805522B2 (ja) 2011-12-26 2015-11-04 株式会社Adeka 粉粒状複合体及び創傷被覆材
AU2013344659B2 (en) * 2012-11-14 2017-10-05 Smith & Nephew, Inc. Stable thermolysin hydrogel
CN103397509A (zh) * 2013-08-07 2013-11-20 武汉纺织大学 一种抗菌吸液纱布的制备方法
CN103724568B (zh) * 2013-12-31 2015-11-18 深圳先进技术研究院 一种抗菌细菌纤维素及其制备方法
CN104162184B (zh) * 2014-05-26 2016-06-15 北京鼎瀚恒海生物科技股份有限公司 一种复合医用敷料及其制备方法
CN104629067B (zh) * 2015-02-16 2017-10-27 东北林业大学 一种再生抗菌性纤维素‑聚乙烯醇复合膜的制备方法
JP6716841B2 (ja) * 2016-02-10 2020-07-01 株式会社アルチザンラボ 止血材
CN105860121A (zh) * 2016-04-06 2016-08-17 东华大学 一种抗菌细菌纤维素材料的制备方法

Also Published As

Publication number Publication date
CN110997018A (zh) 2020-04-10
WO2019026177A1 (ja) 2019-02-07
US20220378974A1 (en) 2022-12-01
US11938230B2 (en) 2024-03-26
US20210085820A1 (en) 2021-03-25
CN115475276A (zh) 2022-12-16
EP3662937A4 (de) 2021-03-10

Similar Documents

Publication Publication Date Title
US11938230B2 (en) Hemostatic material and wound dressing containing same
JP6716841B2 (ja) 止血材
US10314937B2 (en) Biocompatible hemostatic product and preparation method thereof
EP2340053B1 (de) Wundversorgungsvorrichtung
JP6250591B2 (ja) 組織ドレッシングキット
EP3672655A1 (de) Biomaterial und verfahren zur herstellung und verwendung des biomaterials
JP2008532662A (ja) 抗菌創傷包帯の作製方法およびその使用
KR20040047537A (ko) 알데히드 개질된 폴리사카라이드를 함유하는 지혈용 상처드레싱
KR101562604B1 (ko) 운드거즈 제조방법 및 이로부터 제조된 운드거즈
US9681992B2 (en) Wound care device
EP1487506B1 (de) Zubereitung für die wundheilung und zur verhinderung des anhaftens von verbänden an die wunde
CN112870430B (zh) 基于天然多糖的复合凝胶止血粉、其制备方法及应用
CN104031285A (zh) 生物相容性纤维素多糖海绵的制备方法
US20120282320A1 (en) Hemostatic dressing
CN112957519A (zh) 用于制备促进创口愈合的水凝胶的组合物、水凝胶及其制备方法
CN107596433B (zh) 一种具有快速吸液和止血性能的止血粉的制备方法
WO2022191330A1 (ja) 止血材
RU2743425C1 (ru) Гемостатическое средство на основе хитозанового аэрогеля
CN118846197A (zh) 一种贻贝仿生湿态粘附、可控剥离的止血抗菌水凝胶的制备方法及其应用

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200127

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20210209

RIC1 Information provided on ipc code assigned before grant

Ipc: A61L 15/46 20060101ALI20210203BHEP

Ipc: A61L 15/28 20060101AFI20210203BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20221014